Showing 2776 results
-
Press release /New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T…
-
Press release /Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G1 Additionally, statistically significant reduction in C3…
-
Press release /Regardless of body mass index (BMI), Leqvio provided sustained and effective LDL-C reduction of ~50% with two doses a year**, according to pooled analysis of three Phase III studies 1Being overweight…
-
Press release /HER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…
-
Press release /Treatment with Cosentyx® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Pulse Update /
-
Pulse Update /
-
Statement /
-
Story /One man’s fascination with malaria helps fuel the search for new treatments.
-
Story /Follow Dr. Cobos as he works to provide a patient with a new liver and performs surgery using a tiny video camera.